Opinion: We Need More than New Antibiotics to Fight Resistance

Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs.

Written byNeil S. Greenspan and Arturo Casadevall
| 3 min read
antibiotics antibiotics resistance persister bacteria bacteriophage

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, ZMEEL

In the summer of 1924, Calvin Jr., President Coolidge’s youngest son, developed a blister in his third right toe while playing tennis at the White House court. The blister became infected with Staphylococcus aureus (staph), and he died a week later at just 16 years old. Two decades later, penicillin could have saved him, but this drug is now useless against staph because of drug resistance, which has now become a broader crisis in medicine.

Of course, there is an ongoing search for new safe and effective antibiotics, but agents are very difficult to find. Unfortunately, even after the introduction of a new antibiotic, resistance inevitably develops through the evolution of the targeted bacteria in months to years. While we support the ongoing efforts to develop new antibiotics, we thought it would be timely to review other therapeutic approaches beyond antibiotics that are being explored.

One ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies